

Treatment response prediction of neoadjuvant chemotherapy for rectal cancer by deep learning of colonoscopy images

SHINYA KATO^{1,2}, NORIKATSU MIYOSHI^{1,2}, SHIKI FUJINO², SOICHIRO MINAMI^{1,2}, AYUMI NAGAE^{1,2},
RIE HAYASHI^{1,2}, YUKI SEKIDO¹, TSUYOSHI HATA¹, ATSUSHI HAMABE¹, TAKAYUKI OGINO¹,
MITSUYOSHI TEI³, YOSHINORI KAGAWA⁴, HIDEKAZU TAKAHASHI¹, MAMORU UEMURA¹,
HIROFUMI YAMAMOTO¹, YUICHIRO DOKI¹ and HIDETOSHI EGUCHI¹

¹Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871;

²Department of Innovative Oncology Research and Regenerative Medicine, Osaka International Cancer Institute, Osaka 541-8567; ³Department of Surgery, Osaka Rosai Hospital, Sakai, Osaka 591-8025; ⁴Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka 558-8588, Japan

Received January 11, 2023; Accepted August 4, 2023

DOI: 10.3892/ol.2023.14062

Abstract. In current clinical practice, several treatment methods, including neoadjuvant therapy, are being developed to improve overall survival or local recurrence rates for locally advanced rectal cancer. The response to neoadjuvant therapy is usually evaluated using imaging data collected before and after preoperative treatment or postsurgical pathological diagnosis. However, there is a need to accurately predict the response to preoperative treatment before treatment is administered. The present study used a deep learning network to examine colonoscopy images and construct a model to predict the response of rectal cancer to neoadjuvant chemotherapy. A total of 53 patients who underwent preoperative chemotherapy followed by radical resection for advanced rectal cancer at the Osaka University Hospital between January 2011 and August 2019 were retrospectively analyzed. A convolutional neural network model was constructed using 403 images from 43 patients as the learning set. The diagnostic accuracy of the deep learning model was evaluated using 84 images from 10 patients as the validation set. The model demonstrated a sensitivity, specificity, accuracy, positive predictive value and area under the curve of 77.6% (38/49), 62.9% (22/33), 71.4% (60/84), 74.5% (38/51) and 0.713, respectively, in predicting a poor response to neoadjuvant therapy. Overall, deep learning of colonoscopy images may contribute to an accurate prediction of the response of rectal cancer to neoadjuvant chemotherapy.

Introduction

Colorectal cancer (CRC) is the third most common malignancy worldwide and the second most common cause of cancer-associated mortality (1). After the locoregional cancer is treated, CRC often causes distant metastasis, with the liver being the most common site (2). Due to anatomical reasons, patients with rectal cancer (RC) have a higher risk of local recurrence compared with patients with colon cancer, and locally recurrent RC is associated with a poor prognosis (3-5). Therefore, various neoadjuvant therapy approaches have been attempted for stage II or stage III RC to prevent distant metastasis and local recurrence, including neoadjuvant chemotherapy (6-8), neoadjuvant chemoradiotherapy (9-11) and total neoadjuvant therapy (12-14).

Previous studies have indicated that tumor regression detected through imaging after preoperative treatment is associated with long-term prognosis in patients with RC (15,16). In a prospective cohort study, the tumor regression grade assessed through imaging was significantly associated with overall survival and disease-free survival (15). Various efforts have been made to explore the usefulness of serological or genetic biomarkers as predictors of the response to preoperative treatment, although such biomarkers are costly (17,18). The use of regular examinations to predict the response of preoperative treatment is desirable in terms of cost-effectiveness and objectivity. Colonoscopy is typically performed on nearly all patients suspected of having colorectal cancer before surgery to assess tumor size, depth and circumference, followed by biopsy to confirm the diagnosis (19,20). Patients undergoing preoperative treatment are assessed for treatment response by comparing endoscopic images taken before and after preoperative treatment. Colonoscopy images are thus among the most readily available tumor images.

Conventional artificial intelligence (AI) techniques and machine learning have major limitations in analyzing natural data (21). However, deep learning, which has emerged in previous years, excels in learning complex structures with

Correspondence to: Dr Norikatsu Miyoshi, Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
E-mail: nmiyoshi@gesurg.med.osaka-u.ac.jp

Key words: deep learning, rectal cancer, chemotherapy, artificial intelligence, colonoscopy, convolutional neural network

high-dimensional data and has enabled significant advancements in various fields (21,22). Deep learning is applicable to medicine, and AI tools developed in collaboration with AI experts, specialized facilities, companies and physicians are gradually being implemented in practical settings (23-25).

The present research developed a deep learning prediction model to assess the treatment response of RC to neoadjuvant chemotherapy using endoscopic images taken during the initial examination. The prediction accuracy of the model was further investigated. To the best of our knowledge, no report has verified whether deep learning of colonoscopy images from initial examinations can predict the response of RC to neoadjuvant chemotherapy.

Materials and methods

Patients and datasets. The present retrospective study included patients who underwent radical resection for advanced RC after neoadjuvant chemotherapy at Osaka University Hospital (Suita, Japan) between January 2011 and August 2019. The exclusion criteria were incomplete planned neoadjuvant chemotherapy, lack of preserved endoscopic images or missing clinical data. The patient characteristics are summarized in Tables I and SI. The mean age of the patients was 60.2 years (range, 19-77 years), with 33 men and 20 women.

The information and images of the patients were obtained from electronic medical records. Clinical and pathological factors were determined according to the 8th edition of the Union for International Cancer Control Tumor-Node-Metastasis classification (26). Multidetector row computed tomography (MDCT) and magnetic resonance imaging (MRI) were used to preoperatively diagnose progression, including tumor invasion and lymph node metastasis. Lymph nodes with a short axis diameter of ≥ 7 mm on MDCT were considered positive (27). The MDCT parameters were rotation speed of 0.6 s/r, helical pitch of 17.5 mm/r and slice thickness of 0.625 mm. The reconstruction intervals were set to 0.5 mm. MRI was performed using a thin, 3-mm section turbo spin-echo T2-weighted technique with a surface pelvic phased-array coil and a small field of view. Bowel preparation, air insufflation or intravenous antispasmodic agents were not routinely used.

The location and histological grade in response to neoadjuvant chemotherapy were determined according to the Japanese Classification of Colorectal, Appendiceal and Anal Carcinoma (28). The classification of pathological tumor regression grade was based on the guidelines provided by the National Comprehensive Cancer Network (29). R0 resection was defined as no evidence of tumor within 1-mm of the distal, proximal or radial margins, as assessed by the review of the pathologists who were independent from the present study.

Evaluation of clinical response to neoadjuvant chemotherapy. Clinical response to neoadjuvant chemotherapy was assessed by MRI conducted before and after chemotherapy according to the Response Evaluation Criteria in Solid Tumors version 1.1 (30). To simplify the end points, progressive disease and stable disease were defined as poor responder RC (PR-RC), and partial response and complete response as good responder RC (GR-RC).

Colonoscopy. Colonoscopy was performed before and after neoadjuvant chemotherapy. The images were obtained using the EVIS LUCERA video system (Olympus Corporation) and the following colonoscopes: CF-HQ290I, CF-Q260AI, PCF-H290I, PCF-H290I, PCF-Q260AI, CF-H290I and CF-H260AI (Olympus Corporation). All these endoscopes were equipped with high-definition-compatible charge-coupled devices that enabled high-quality imaging. Although the endoscopes had different scope diameters, viewing angles and focal lengths, they yielded images of similar quality. All images had at least one RC lesion, and multiple images of the same lesion were produced to illustrate the differences in angle, distance and extension of the mucosa. Images that include at least part of the tumor area within the field of view were selected. The present study did not limit images of the target by the distance from the tumor surface. All images were captured under white light after adjusting white balance. Poor-quality images due to halos, blurred focus or mucus were excluded from the current study.

Deep learning. A model was constructed using deep learning of colonoscopy images to predict PR-RC or GR-RC. Overall, two models were constructed, one based on pre-treatment images and the other based on post-treatment images (Figs. 1B and S1A). AlexNet (31) in Matlab 2022b (MathWorks) was used as the network for building the models (32). Deep Learning Toolbox (MathWorks; <https://jp.mathworks.com/products/deep-learning.html>) and Image Processing Toolbox (MathWorks; <https://jp.mathworks.com/products/image.html>) were used as toolboxes for constructing the deep learning models. To eliminate unnecessary background information and focus on the tumor, each image was cropped to a square shape and resized to a predetermined size prior to the analysis. Occlusion was used to assess the impact input images and determine their influence on the classification results.

Statistical analyses. The differences in clinicopathological factors between the two groups were analyzed using Fisher's exact test. Continuous variables that had a non-parametric distribution were analyzed using the Mann-Whitney U test. The Shapiro-Wilk test was used to test for normality. The continuous variables are presented as the median \pm interquartile range. $P < 0.05$ was considered to indicate a statistically significant difference for all analyses. All statistical analyses were performed using the JMP Pro version 16 (SAS Institute, Inc.).

Results

A total of 53 of the 71 patients were included in the present study. A total of 322 pre-treatment images from 43 patients who underwent neoadjuvant chemotherapy for advanced RC between January 2011 and March 2018 were included in the learning set (Table I; Fig. 1). A validation set was created that included 84 images obtained during the pre-treatment examination of 10 patients who underwent neoadjuvant chemotherapy between June 2018 and August 2019. All patients underwent total mesorectal excision with R0 resection 3 to 6 weeks after completing neoadjuvant chemotherapy. In the learning set, patients with PR-RC had more advanced

Table I. Clinicopathological backgrounds.

Variables	Learning set (n=43)	Validation set (n=10)	P-value
Age, years			
Median (IQR)	64 (56-71)	59 (37-65)	0.069 ^a
Sex, n (%)			
Male	28 (65.1)	5 (50.0)	0.475 ^b
Female	15 (34.9)	5 (50.0)	
Body mass index			
Median (IQR)	22 (20.4-24.5)	24.1 (16.3-25.5)	0.139 ^a
Carcinoembryonic antigen, ng/ml			
Median (IQR)	5 (2-9)	4.5 (3-17.8)	0.731 ^a
Carbohydrate antigen 19-9, U/ml			
Median (IQR)	18 (6 -39)	27.5 (8.6-52.9)	0.413 ^a
Tumor location, n (%)			
Ra	4 (9.3)	1 (10.0)	>0.999 ^b
Rb	39 (90.7)	9 (90.0)	
Histological grade, n (%)			
Tub, no evidence of cancer	38 (88.4)	9 (90.0)	>0.999 ^b
Muc, Por	5 (11.6)	1 (10.0)	
Lymphatic invasion, n (%)			
Present	19 (44.2)	5 (50.0)	>0.999 ^b
Absent	24 (55.8%)	5 (50.0)	
Vascular invasion, n (%)			
Present	13 (30.2)	3 (30.0)	>0.999 ^b
absent	30 (69.8)	7 (70.0)	
Pathological tumor invasion, n (%)			
T0, Tis, T1, T2	22 (51.2)	5 (50.0)	>0.999 ^b
T3, T4	21 (48.8)	5 (50.0)	
Pathological lymph node metastasis, n (%)			
Present	15 (34.9)	2 (20.0)	0.471 ^b
Absent	28 (65.1)	8 (80.0)	
Pathological tumor regression grade, n (%)			
Grade 0, 1, 2	6 (14.0)	3 (30.0)	0.346 ^b
Grade 3	37 (86.0)	7 (70.0)	
Clinical response to NAC, n (%)			
Poor response	22 (51.2)	5 (50.0)	>0.999 ^b
Good response	21 (48.8)	5 (50.0)	
Regimens of NAC, n (%)			
Capecitabine, oxaliplatin containing	42 (97.7)	10 (100.0)	>0.999 ^b
Capecitabin and Bevacizumab	1 (2.3)	0 (0.0)	

^aMann-Whitney U test, ^bFisher's exact test. Location and histological grade were determined according to the Japanese Classification of Colorectal Carcinoma (9th edition). Clinical response was determined according to Response Evaluation Criteria in Solid Tumors version 1.1. Progressive disease and stable disease were defined as poor response, and partial response and complete response were defined as good response. Ra, upper rectum; Rb, lower rectum; IQR, interquartile range; Tub, tubular adenocarcinoma; Por, poorly differentiated adenocarcinoma; NAC, neo-adjuvant chemotherapy.

pathological tumor invasion and pathological lymph node metastasis compared with that observed among patients GR-RC, reflecting the clinical efficacy of neoadjuvant chemotherapy (Table II).

The present study constructed a prediction model based on deep learning of pre-treatment images and clinical responses in the learning set. The accuracy of pre-chemotherapy deep learning model in predicting the response to chemotherapy in the




Figure 1. Overview of the deep learning model. (A) Study population diagram. (B) Deep learning was performed using 322 colonoscopy images taken before neoadjuvant chemotherapy. The validity of the constructed prediction model was verified with an independent validation set including 84 images.




Figure 2. Receiver operating characteristic curves of the deep learning model. (A) Area under the curve value of the learning set was 0.990. (B) Area under the curve value of the validation set was 0.713.

validation set is shown in Table III. In the validation dataset, 49 images were taken from five patients who were clinically diagnosed as PR-RC, and 35 images were taken from five patients who were clinically diagnosed as GR-RC. When using the validation set, the sensitivity, specificity, positive predictive value, accuracy and area under the curve (AUC) of the model in predicting PR-RC status were 77.6% (38/49), 62.9% (22/35), 74.5% (38/51), 71.4% (60/84) and 0.713, respectively (Table II; Fig. 2).

Prediction errors where the model was unable to predict response occurred when the AI focused on areas other than the tumor (Fig. 3). The percentages of incorrect predictions where the AI focused on tumor area were 36.4% for PR-RC and 15.4% for GR-RC. The percentage of incorrect predictions where the AI focused on the normal mucosa was 54.5% for PR-RC and 46.1% for GR-RC (Table IV). The percentages of incorrect predictions focused on bleeding were 9.1% for

Table II. Clinicopathological features of the learning set.

Variables	Poor responder (n=21)	Good responder (n=22)	P-value
Age, years			
Median (IQR)	62 (56-71)	64.5 (54-70)	0.913 ^a
Sex, n (%)			
Male	16 (76.2)	12 (54.5)	0.203 ^b
Female	5 (23.8)	10 (45.5)	
Body mass index			
Median (IQR)	22.8 (20.4-24.8)	21.9 (20.1-23.6)	0.671 ^a
Carcinoembryonic Antigen, ng/ml			
Median (IQR)	6 (3-10)	3 (2-9.75)	0.413 ^a
Carbohydrate antigen 19-9, U/ml			
Median (IQR)	18 (5.75-46.5)	12 (5-40)	0.913 ^a
Tumor location, n (%)			
Ra	2 (9.5)	0 (0.0)	0.233 ^b
Rb	19 (90.5)	22 (100.0)	
Histological grade, n (%)			
Tubular adenocarcinoma	17 (81.0)	21 (95.5)	0.185 ^b
Muc or por	4 (19.0)	1 (4.5)	
Lymphatic invasion, n (%)			
Present	11 (52.4)	8 (36.4)	0.364 ^b
Absent	10 (47.6)	14 (63.6)	
Vascular invasion, n (%)			
Present	8 (38.1)	5 (22.7)	0.332 ^b
Absent	13 (61.9)	17 (77.3)	
Pathological tumor invasion, n (%)			
T1, T2	6 (28.6)	16 (72.7)	0.006 ^{b,c}
T3, T4	15 (71.4)	6 (27.3)	
Pathological lymph node metastasis, n (%)			
Present	11 (52.4)	4 (18.2)	0.027 ^{b,c}
Absent	10 (47.6)	18 (81.8)	
Pathological tumor regression grade, n (%)			
Grade 0, 1, 2	1 (4.8)	5 (22.7)	0.185 ^b
Grade 3	20 (95.2)	17 (77.3)	

^aMann-Whitney U test, ^bFisher's exact test. ^cP<0.05. Location and histological grade were determined according to the Japanese Classification of Colorectal Carcinoma (9th edition). Clinical response was determined according to Response Evaluation Criteria in Solid Tumors version 1.1. Progressive disease and stable disease were defined as poor response, and partial response and complete response were defined as good response. Ra, upper rectum; Rb, lower rectum; NAC, neo-adjuvant chemotherapy; IQR, interquartile range.

PR-RC and 38.5% for GR-RC. AI focus on non-tumor areas was considered to be partly responsible for the incorrect AI predictions.

Finally, the present study constructed another prediction model based on deep learning of clinical responses and colonoscopy images of the same patient dataset after preoperative chemotherapy, and its accuracy was verified. The same learning and validation sets were used to test the model based on colonoscopy images after preoperative chemotherapy. The accuracy of the model is shown in Table SII. The post-chemotherapy model had a sensitivity of 40.5% (17/42), specificity of 56.1% (23/41), accuracy of 48.2% (40/83) and AUC value of

0.592 (Fig. SIC). The post-chemotherapy deep learning model had inferior predictive performance to the model based on pre-chemotherapy endoscopic images.

Discussion

AI technology has achieved unprecedented success in various fields. Deep learning, which is a subset of machine learning that focuses on deep artificial neural networks (21,25), has been used in numerous areas of oncology, ranging from cancer detection and classification to the molecular characterization of tumors and their microenvironment (33,34), drug

Table III. Prediction accuracy in the validation set of AI prediction models constructed by deep learning of colonoscopy images before neoadjuvant chemotherapy.

Clinical response	AI prediction		Total
	Poor responder	Good responder	
Poor responder	38 images	11 images	49 images
Good responder	13 images	22 images	35 images

Sensitivity, 77.6% (38/49); specificity, 62.9% (22/35); positive predictive value, 74.5% (38/51); accuracy, 71.4% (60/84). Clinical response was determined according to Response Evaluation Criteria in Solid Tumors version 1.1. Progressive disease and stable disease were defined as poor response, and partial response and complete response were defined as good response. AI, artificial intelligence.

Table IV. Focused area of incorrect AI prediction in the validation set.

Clinical response	Focused area of incorrect AI prediction			Total
	Tumor area	Other area		
		Normal mucosa	Bleeding	
Poor responder	4 images (36.4%)	6 images (54.5%)	1 image (9.1%)	11 images
Good responder	2 images (15.4%)	6 images (46.1%)	5 images (38.5%)	13 images

Clinical response was determined according to Response Evaluation Criteria in Solid Tumors version 1.1. Progressive disease and stable disease were defined as poor response, and partial response and complete response were defined as good response. AI, artificial intelligence.

discovery (35) and prediction of distant metastasis (36). In the context of predicting the efficacy of preoperative treatment for RC, deep learning based on MRI images and hematoxylin-eosin (HE) staining images has been reportedly useful in predicting complete response to preoperative chemoradiotherapy (37). The colonoscopy that was the source of images in the current study was an examination conducted for nearly all patients with RC who received preoperative treatment, meaning it was relatively straightforward to implement a deep learning model using this modality in clinical practice.

The present study examined the ability of deep learning models based on colonoscopy images to predict the response of RC to preoperative chemotherapy. This study did not include the patients who were provided neoadjuvant radiation therapy or neoadjuvant chemoradiotherapy because the mechanisms of antitumor effects of chemotherapy and radiation therapy differ. The model based on colonoscopy images taken before preoperative chemotherapy was able to differentiate PR-RC from GR-RC with a sensitivity of 77.6% and accuracy of 71.4% with an AUC of 0.713. Furthermore, the present study created a program to visualize the parts of the image that the AI recognized and diagnosed using a color map (38-40). AI-based image recognition detects the location of the tumor as well as the information around the tumor, including the bleeding area, which might influence the prediction accuracy. Implementing a program that accurately recognizes the tumor surface may improve the accuracy of the prediction. The analyses in the study did not exclude patients who used molecularly targeted drugs.

The present study also attempted to create another model using pre-treatment images except for the patients who used molecularly targeted drugs and the accuracy was assessed. The sensitivity and accuracy of the model that excluded the patient on targeted therapy were 71.4% (35/49) and 65.5% (55/84), respectively.

The current study defined MRI-detected clinical response as the outcome of deep learning models because MRI assessments of tumor regression grade are imaging markers that predict survival outcomes (15). Pathologic tumor regression grading is based on the percentage of fibrosis in the surgical specimen and correlates with survival at a greater statistical significance (15,16); however, by applying a similar approach with MRI, the present study was able to assess tumor response and predict the outcome of patients before surgery (15). Future validation studies are needed to determine the tumor response and survival outcome before chemotherapy using deep learning and endoscopic images.

To the best of our knowledge, the present study was the first to report on the utility of deep learning based on pretreatment endoscopic images to predict the treatment response to neoadjuvant chemotherapy. The current results had several important implications. The first was the possibility of improving the model by combining the modality with other modalities, such as MRI images and clinicopathological factors. Recently, deep learning prediction models have combined multiple modalities to predict the clinical efficacy of preoperative RC treatment. Predictive models combining multiple modalities significantly outperform




Figure 3. Examples for attention color mapping on six colonoscopy images. (A) Examples of correct AI prediction. (B) Incorrect AI prediction due to focus on normal mucosa or bleeding. White arrows indicate the normal mucosa that the AI focused on. White arrow heads indicate the bleeding that the AI focused on. AI, artificial intelligence; CNN, convolutional neural network; PR, poor response; GR, good response.

predictive models involving individual modalities (37). Secondly, the application of deep learning to pretreatment endoscopic images could serve as a potential method for predicting the complete response to preoperative chemoradiotherapy. In the future, if deep learning models based on endoscopic images demonstrate improved predictive accuracy compared with models based on histological images, their significance must be further emphasized through future validation. Thirdly, pre-chemotherapy endoscopic images may be more useful compared with post-chemotherapy

images to build models predicting the effect of chemotherapy. The present study revealed that the deep learning model based on pre-chemotherapy images was more accurate in predicting chemotherapy efficacy compared with that using post-chemotherapy images. Furthermore, the present study validated a combination model; however, the sensitivity (20.0%) and accuracy (40.0%) were so low that the model was not considered useful. The deep learning model based on pre-chemotherapy images may capture features of tumor surface structures that reflect chemotherapy responsiveness.

The present results were limited by the potential risk of overfitting due to the use of data from a single-center and small sample size. Additionally, the current results are limited by uncertain reproducibility due to the lack of prospective validation; therefore, additional validation is required.

In conclusion, deep learning based on endoscopic images may allow for enhanced accuracy when predicting the response of RC to neoadjuvant chemotherapy. There is a need to collect more images and investigate additional image features to improve prediction accuracy.

Acknowledgements

The authors would like to thank Mr. Hiroyuki Hishida and Ms. Misa Taguchi (The MathWorks Japan, Inc., Tokyo, Japan) for their technical assistance and support in program development.

Funding

This study was supported by the Council for Science, Technology and Innovation, Cross-Ministerial Strategic Innovation Promotion Program, 'Innovative AI Hospital System' (Funding Agency: National Institute of Biomedical Innovation, Health and Nutrition). (grant no. SIPAIH22D03) and the Japanese Foundation for Research and Promotion of Endoscopy Grant.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

SK, NM, SF, MU, YD and HE conceived and designed the study. Material preparation and data collection were performed by SK, SM, AN and RH. Data analyses were performed by SK, NM, YS, TH, AH, TO, HT, MU, HY, MT and YK. The first draft of the manuscript was written by SK, and all the authors commented on previous versions of the manuscript. SK and NM confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

This study was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants. This study was approved by the Institutional Review Board of Osaka University (approval no. 19020).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71: 209-249, 2021.
- Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH and Brennan MF: Liver resection for colorectal metastases. *J Clin Oncol* 15: 938-946, 1997.
- Rajput A and Bullard Dunn K: Surgical management of rectal cancer. *Semin Oncol* 34: 241-249, 2007.
- Weiser MR, Landmann RG, Wong WD, Shia J, Guillem JG, Temple LK, Minsky BD, Cohen AM and Paty PB: Surgical salvage of recurrent rectal cancer after transanal excision. *Dis Colon Rectum* 48: 1169-1175, 2005.
- Wiig JN, Larsen SG and Giercksky KE: Operative treatment of locally recurrent rectal cancer. *Recent Results Cancer Res* 165: 136-147, 2005.
- Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, *et al*: Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: A pilot trial. *J Clin Oncol* 32: 513-518, 2014.
- Glynn-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, *et al*: Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. *BMC Cancer* 15: 764, 2015.
- Kamiya T, Uehara K, Nakayama G, Ishigure K, Kobayashi S, Hiramatsu K, Nakayama H, Yamashita K, Sakamoto E, Tojima Y, *et al*: Early results of multicenter phase II trial of peri-operative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study. *Eur J Surg Oncol* 42: 829-835, 2016.
- Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B and Gunnarsson U: Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. *J Clin Oncol* 23: 5644-5650, 2005.
- Peeters KC, Marijnen CA, Nagtegaal ID, Kranenburg EK, Putter H, Wiggers T, Rutten H, Pahlman L, Glimelius B, Leer JW, *et al*: The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. *Ann Surg* 246: 693-701, 2007.
- Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, *et al*: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. *J Clin Oncol* 30: 1926-1933, 2012.
- Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, Cencelewicz A, Spałek M, Polkowski W, Jankiewicz M, *et al*: Long-course preoperative chemoradiation versus 5x5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study. *Ann Oncol* 30: 1298-1303, 2019.
- Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenburg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, *et al*: Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial. *Lancet Oncol* 22: 29-42, 2021.
- Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, Liu WY, Chen SL, Li S, Lu NN, *et al*: Multicenter, randomized, Phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). *J Clin Oncol* 40: 1681-1692, 2022.
- Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, Quirke P, Sebag-Montefiore D, Moran B, Heald R, *et al*: Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. *J Clin Oncol* 29: 3753-3760, 2011.
- Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, Becker H, Ghadimi M, Mrak K, Merkel S, *et al*: Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: Updated results of the CAO/ARO/AIO-94 trial. *J Clin Oncol* 32: 1554-1562, 2014.

17. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Füzesi L, Langer C, Becker H, Liersch T, *et al*: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. *J Clin Oncol* 23: 1826-1838, 2005.
18. Cercek A, Dos Santos Fernandes G, Roxburgh CS, Ganesh K, Ng S, Sanchez-Vega F, Yaeger R, Segal NH, Reidy-Lagunes DL, Varghese AM, *et al*: Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. *Clin Cancer Res* 26: 3271-3279, 2020.
19. Lynch ML and Brand MI: Preoperative evaluation and oncologic principles of colon cancer surgery. *Clin Colon Rectal Surg* 18: 163-173, 2005.
20. Arteaga-González I, Martín-Malagón A, Fernández EM, Arranz-Durán J, Parra-Blanco A, Nicolas-Perez D, Quintero-Carrión E, Luis HD and Carrillo-Pallares A: The use of preoperative endoscopic tattooing in laparoscopic colorectal cancer surgery for endoscopically advanced tumors: A prospective comparative clinical study. *World J Surg* 30: 605-611, 2006.
21. LeCun Y, Bengio Y and Hinton G: Deep learning. *Nature* 521: 436-444, 2015.
22. Duch W, Swaminathan K and Meller J: Artificial intelligence approaches for rational drug design and discovery. *Curr Pharm Des* 13: 1497-1508, 2007.
23. Ehteshami Bejnordi B, Veta M, Johannes van Diest P, van Ginneken B, Karssemeijer N, Litjens G, van der Laak J, Hermsen M, Manson QF, Balkenhol M, *et al*: Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. *JAMA* 318: 2199-2210, 2017.
24. Khosravi P, Kazemi E, Imielinski M, Elemento O and Hajirasouliha I: Deep Convolutional neural networks enable discrimination of heterogeneous digital pathology images. *EBioMedicine* 27: 317-328, 2018.
25. Bhinder B, Gilvary C, Madhukar NS and Elemento O: Artificial intelligence in cancer research and precision medicine. *Cancer Discov* 11: 900-915, 2021.
26. TNM Classification of Malignant Tumours, Eighth Edition. Wiley Blackwell, Hoboken, 2016.
27. Yukimoto R, Uemura M, Tsuboyama T, Sekido Y, Hata T, Ogino T, Miyoshi N, Takahashi H, Kida A, Furuyashiki M, *et al*: Efficacy of PET/CT in diagnosis of regional lymph node metastases in patients with colorectal cancer: Retrospective cohort study. *BJS Open* 6: 2022.
28. Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: The 3d English Edition [Secondary Publication]. *J Anus Rectum Colon* 3: 175-195, 2019.
29. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, *et al*: Rectal cancer, version 2.2022. NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 20: 1139-1167, 2022.
30. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, *et al*: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 45: 228-247, 2009.
31. Krizhevsky AS and Hinton GEI: Imagenet classification with deep convolutional neural networks. *Adv Neural Inf Process Syst* 25: 1097-1105, 2012.
32. Minami S, Saso K, Miyoshi N, Fujino S, Kato S, Sekido Y, Hata T, Ogino T, Takahashi H, Uemura M, *et al*: Diagnosis of depth of submucosal invasion in colorectal cancer with AI using deep learning. *Cancers (Basel)* 14: 5361, 2022.
33. Yamashita R, Long J, Longacre T, Peng L, Berry G, Martin B, Higgins J, Rubin DL and Shen J: Deep learning model for the prediction of microsatellite instability in colorectal cancer: A diagnostic study. *Lancet Oncol* 22: 132-141, 2021.
34. Jiao Y, Li J, Qian C and Fei S: Deep learning-based tumor micro-environment analysis in colon adenocarcinoma histopathological whole-slide images. *Comput Methods Programs Biomed* 204: 106047, 2021.
35. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK and Kumar P: Artificial intelligence to deep learning: Machine intelligence approach for drug discovery. *Mol Divers* 25: 1315-1360, 2021.
36. Liu X, Zhang D, Liu Z, Li Z, Xie P, Sun K, Wei W, Dai W, Tang Z, Ding Y, *et al*: Deep learning radiomics-based prediction of distant metastasis in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy: A multicentre study. *EBioMedicine* 69: 103442, 2021.
37. Feng L, Liu Z, Li C, Li Z, Lou X, Shao L, Wang Y, Huang Y, Chen H, Pang X, *et al*: Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A multicentre observational study. *Lancet Digit Health* 4: e8-e17, 2022.
38. Miyoshi N: AI application for surgery. *J Jpn Soc Precis Eng* 88: 9-11, 2022.
39. Lu L, Dercle L, Zhao B and Schwartz LH: Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging. *Nat Commun* 12: 6654, 2021.
40. Horvat N, Veeraraghavan H, Khan M, Blazic I, Zheng J, Capanu M, Sala E, Garcia-Aguilar J, Gollub MJ and Petkovska I: MR Imaging of rectal cancer: Radiomics analysis to assess treatment response after neoadjuvant therapy. *Radiology* 287: 833-843, 2018.



Copyright © 2023 Kato et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.